According to Zhitong Finance App News, Yaojiekang-B (02617.HK) announced that the company's self-developed Class 1 drug Jientai® (tengotinib tablets) has been conditionally approved for marketing by the National Drug Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received systemic treatment and FGFR inhibitors in the past and have fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement. In September 2026, the “Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Biliary Malignant Tumors” was officially released, and Gentec® was included as a Level II Recommended Class 2A guideline for the treatment of advanced biliary tract malignancies. Gentech® is the first drug marketed and approved for this indication in China. It is expected to benefit drug-resistant patients with FGFR mutant cholangiocarcinoma and fill gaps in guidelines for the treatment of advanced biliary tract malignancies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.